Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CDT vs AAPG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AAPG Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

AAPG Overall Winner 6-Pillar Tally: CDT 2 – 3 AAPG (1 Tie) Matrix Metrics: CDT 4 – 6 AAPG

As of Nov 20, 2026, Ascentage Pharma Group International American Depository Shares (AAPG) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CDT carries a Unified Composite Score of 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin), whereas AAPG carries 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin).

  • Defensive Composite Rating Caution: Although AAPG compares more favorably head-to-head, both CDT (31.6/100 SELL) and AAPG (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: CDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile AAPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDT vs AAPG
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -17.75β · 10175% Vol
Unified Composite Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -58.9%), weak momentum, RSI 44
RSI-14: 44.1 · SMA20: $0.31 · SMA50: $0.40
AAPG NASDAQ Head-to-Head Winner
Ascentage Pharma Group International American Depository Shares
Pharmaceutical Preparations
$11.97
-3.78% 1D
Market Cap $1.2B
TTM Revenue $643M
Forward P/E 8.4x
Beta / 30D Vol 1.36β · 64% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 29
RSI-14: 28.8 · SMA20: $14.33 · SMA50: $14.97

6-Pillar Scorecard Institutional Category Breakdown (CDT 2 – 3 AAPG)

Columns: Metric · CDT · AAPG
1. Valuation Multiples AAPG
Forward P/E N/M 8.4x
Trailing P/E N/M 8.4x
PEG Ratio N/M N/M
EV / Revenue N/M 1.8x
2. Growth & Scale AAPG
Revenue Growth (YoY) +0.0% +29.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $643M
Market Cap $507,528 $1.2B
3. Profitability & Quality CDT
Gross Margin N/A 93.9%
Operating Margin 0.0% -219.5%
Net Profit Margin 0.0% -228.5%
Return on Equity (ROE) -69.7% -236.6%
4. Balance Sheet & Cash Flow CDT
Cash Generation (TTM) N/A -$1.34B EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $435,000 Net Debt (0.01x D/E) $0.89 Book/Sh · -236.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AAPG
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDT (4) vs AAPG (6)
Institutional Metric CDT AAPG Criterion Row Edge
Market Capitalization
Scale
$507,528 $1.2B Larger Scale AAPG
Trailing P/E Ratio
Valuation
N/M 8.4x Lower Multiple AAPG
Forward P/E Ratio
Valuation
N/M 8.4x Lower Multiple AAPG
Revenue Growth (YoY)
Growth
+0.0% +29.3% Higher Growth AAPG
Operating Margin (TTM)
Profitability
0.0% -219.5% Higher Margin CDT
Net Profit Margin
Profitability
0.0% -228.5% Higher Margin CDT
Return on Equity (ROE)
Capital Efficiency
-69.7% -236.6% Higher ROE CDT
52-Week Range Position
Momentum
2% ($0–$11) 0% ($12–$34) Stronger Trend CDT
Beta / 30D Volatility
Risk Regime
-17.75β · 10175% Vol 1.36β · 64% Vol Lower Realized Risk AAPG
Unified Institutional Score
Composite Signal
31.6 / 100 (SELL) 37.1 / 100 (SELL) Higher Composite AAPG
Trailing 12M Revenue (USD)
Operating Scale
N/A $643M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 93.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($435,000 Net Debt (0.01x D/E)) -$1.34B EBITDA ($0.89 Book/Sh · -236.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDT +96.56 pp
CDT: +76.79% · AAPG: -19.77%
3M Horizon AAPG +62.39 pp
CDT: -90.76% · AAPG: -28.37%
6M Horizon AAPG +41.82 pp
CDT: -81.3% · AAPG: -39.48%
1Y Horizon AAPG +23.95 pp
CDT: -86.78% · AAPG: -62.83%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDT vs AAPG. Trailing 12-month operating profitability (CDT 0.0% vs AAPG -219.5%) and valuation multiples (CDT N/M vs AAPG 8.4x Forward P/E) are benchmarked directly in Pillar 4 below.

CDT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.7% · N/M
AAPG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$643M
Gross Margin93.9%
Op. Margin-219.5%
ROE / Fwd P/E-236.6% · 8.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDT BREAKDOWN
163d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AAPG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AAPG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $507,528 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AAPG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and -219.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDT vs AAPG Key Questions & Quantitative Answers

As of Nov 20, 2026, Ascentage Pharma Group International American Depository Shares (AAPG) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CDT carries a Unified Composite Score of 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin), whereas AAPG carries 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin). Defensive Composite Rating Caution: Although AAPG compares more favorably head-to-head, both CDT (31.6/100 SELL) and AAPG (37.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: CDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile AAPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AAPG leads the Growth & Scale pillar: CDT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AAPG at +29.3% YoY revenue growth and +0.0% YoY earnings growth on $643M TTM revenue (93.9% gross margin, -219.5% operating margin). On trailing 12-month operating scale, CDT generates N/A in USD-normalized revenue versus $643M for AAPG. In operating R&D and SG&A reinvestment, CDT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AAPG.

AAPG screens cheaper on headline valuation multiples. CDT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AAPG trades at 8.4x Forward P/E, 8.4x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDT (-69.7% ROE) versus AAPG (-236.6% ROE) capital efficiency.

In options market volatility and institutional positioning, CDT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (-17.75β · 10175% Vol realized risk). By comparison, AAPG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.36β · 64% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.